Drugs of UDCA

Drugs of UDCA Market Outlook

The global Ursodeoxycholic Acid (UDCA) Drugs market is projected to reach approximately USD 2.3 billion by 2028, growing at a CAGR of about 5.4% during the forecast period of 2023 to 2028. This robust growth is primarily driven by the rising prevalence of liver diseases and gallstones, alongside an increasing awareness of the benefits of UDCA in treating various hepatic disorders. Additionally, the expansion of healthcare facilities and advancements in pharmaceutical research continue to fuel demand for effective therapeutics in managing liver-related conditions. The growing geriatric population, who are more prone to liver dysfunction, further exacerbates the market growth, creating significant opportunities for pharmaceutical companies to innovate and expand their product offerings. Furthermore, regulatory advancements and favorable reimbursement policies are also expected to play a crucial role in enhancing market accessibility and affordability for patients worldwide.

Growth Factor of the Market

The growth of the UDCA drugs market can be attributed to several key factors. Firstly, the increasing incidence of chronic liver diseases, including primary biliary cholangitis and liver cirrhosis, is driving the demand for effective treatment options. As healthcare providers and patients seek better management strategies for these conditions, the role of UDCA as a therapeutic agent is becoming more prominent. Secondly, the rising awareness among healthcare professionals regarding the clinical benefits of UDCA is contributing to its growing adoption across various treatment protocols. Additionally, ongoing research and development aimed at enhancing the efficacy and safety profiles of UDCA formulations are expected to further boost market growth. Moreover, the shift towards online healthcare services and telemedicine has made it easier for patients to access these drugs, thereby increasing market penetration. Lastly, favorable government initiatives and policy frameworks that support the development and distribution of UDCA drugs are expected to sustain the growth momentum in the coming years.

Key Highlights of the Market

• The global UDCA drugs market is expected to grow at a CAGR of 5.4% from 2023 to 2028.
• North America holds the largest market share, driven by advanced healthcare infrastructure and high healthcare expenditure.
• Increasing awareness about liver health and the effectiveness of UDCA in treating various conditions is fueling demand.
• The product type segment is dominated by tablets, which are widely preferred by healthcare providers and patients alike.
• Online pharmacies are emerging as a significant distribution channel, providing patients with easier access to medications.

By Product Type

Tablets :

Tablets are the most commonly used form of UDCA drugs, primarily due to their convenience and ease of administration. They are favored both by healthcare providers and patients, as they offer precise dosage and are relatively easy to swallow. The tablet form also allows for extended shelf life and easier storage, making it a practical choice in numerous healthcare settings. The highly standardized production processes ensure that tablets maintain consistent quality and effectiveness, which boosts their reliability as a treatment option. Additionally, the availability of various dosages caters to the diverse needs of patients, allowing for personalized treatment plans. The increasing prevalence of liver diseases is expected to further enhance the demand for tablets, positioning them as a leading product type in the UDCA market.

Capsules :

Capsules represent another significant segment in the UDCA market, providing an alternative to tablets with some distinct advantages. They are often preferred for their ability to mask unpleasant tastes and odors, which can enhance patient compliance. Capsules can also be formulated with various release mechanisms, such as extended-release, which can help in managing dosage frequency and improving therapeutic outcomes. The gelatin or vegetarian casing used in capsules can also improve the bioavailability of active ingredients, making them an attractive choice for patients requiring enhanced efficacy. As the healthcare industry recognizes the importance of adherence to treatment regimens, the usage of capsules is anticipated to grow, supported by ongoing research and product innovation aimed at optimizing their formulations.

Injectable :

Injectable forms of UDCA drugs are increasingly utilized in clinical settings, particularly for patients who may have difficulty swallowing oral medications. This form allows for rapid drug delivery directly into the bloodstream, ensuring immediate therapeutic action, which is particularly important in acute liver conditions. Injectable formulations are often administered in controlled healthcare environments, such as hospitals, where patient monitoring is feasible. Furthermore, the development of long-acting injectable profiles could potentially reduce the frequency of administration, fostering greater patient adherence. The rise in hospital admissions for liver-related ailments is likely to propel the injectable segment’s growth, as healthcare providers seek efficient and quick treatment methods for their patients.

Suspension :

Suspensions are a viable alternative for patients who may have difficulty swallowing pills or capsules, particularly children or the elderly. This liquid form allows for flexible dosing, making it easier to tailor treatments to individual patient needs. The palatability of suspensions can enhance patient compliance, as flavors and sweeteners can be added to make the medication more enjoyable to take. The growth of the suspension segment is also supported by the increasing prevalence of liver diseases in demographics that may prefer or require non-solid dosage forms. Pharmaceutical companies are focusing their research efforts on developing stable and effective suspension formulations, which are likely to drive the demand for this product type further.

Gel :

Gel formulations of UDCA drugs are an emerging segment that provides unique advantages, particularly for localized treatment applications. They can offer targeted delivery of the active ingredient to specific sites within the gastrointestinal tract, which can enhance therapeutic efficacy. The gel form can also facilitate better absorption of UDCA, improving overall bioavailability. Such formulations may appeal to patients looking for alternatives to traditional oral or injectable medications, especially in cases where localized action is required. As research progresses in the formulation of gels, the segment is expected to witness growth driven by innovative applications in treating liver and gallbladder disorders.

By Application

Gallstones :

Gallstones are one of the primary applications of UDCA drugs, as the compound is known for its ability to dissolve cholesterol gallstones, thereby reducing the need for surgical interventions. The effectiveness of UDCA in treating gallstones makes it a preferred choice among healthcare practitioners, particularly for patients who are not suitable candidates for surgery. Increasing awareness about the repercussions of untreated gallstones, coupled with the growing prevalence of obesity, which is a significant risk factor, is driving the demand for UDCA in this application. Moreover, clinical studies supporting the efficacy of UDCA in managing gallstones are further fueling its adoption, solidifying its position within the UDCA drugs market.

Primary Biliary Cholangitis :

Primary biliary cholangitis (PBC) is a chronic disease that affects the bile ducts in the liver, leading to progressive liver damage. UDCA has been recognized as an effective treatment for PBC, helping to improve liver function and slow disease progression. The growing prevalence of autoimmune diseases, including PBC, is significantly contributing to the demand for UDCA drugs in this application. Furthermore, the increasing recognition of the need for long-term management of PBC among healthcare providers is promoting further adoption of UDCA as a part of standard treatment protocols. As awareness increases and more patients are diagnosed, the application of UDCA in treating PBC is expected to expand considerably in the coming years.

Liver Diseases :

The application of UDCA in various liver diseases is broadening as more research highlights its potential benefits. Conditions such as non-alcoholic fatty liver disease (NAFLD) and liver cirrhosis are increasingly being treated with UDCA, due to its hepatoprotective properties. The rising incidence of liver-related disorders, driven by factors such as unhealthy dietary habits and alcohol consumption, is propelling the demand for effective therapeutic options in this segment. Continuous clinical trials and studies are revealing new insights into the benefits of UDCA in managing liver diseases, which is likely to foster market growth. The versatility of UDCA as a treatment option for multiple liver conditions underscores its significance in the overall UDCA drugs market.

Cystic Fibrosis :

Cystic fibrosis (CF) is a genetic disorder that significantly affects lung and digestive function. Recent studies have indicated that UDCA may have beneficial effects on the liver in CF patients, as the disease can lead to liver complications. The rising awareness about the relation between CF and liver function is stimulating demand for UDCA as a part of comprehensive treatment regimens. As more healthcare professionals recognize the potential benefits of UDCA for managing liver health in CF patients, the application of this drug is expected to grow. The increasing number of CF diagnoses and the subsequent need for multidisciplinary treatment approaches are key factors driving growth in this segment.

Others :

In addition to the aforementioned applications, UDCA is being explored for use in various other conditions, including certain metabolic disorders and cholestatic liver diseases. Research is ongoing to better understand the full potential of UDCA in addressing a wider range of pathologies. The growing body of evidence supporting its efficacy in these lesser-known applications could expand the market significantly. Furthermore, as new clinical trials emerge and establish UDCA's effectiveness in treating additional conditions, the 'Others' segment is likely to witness enhanced attention from pharmaceutical manufacturers and healthcare providers alike, contributing to market growth.

By Distribution Channel

Hospital Pharmacies :

Hospital pharmacies play a critical role in the distribution of UDCA drugs, particularly for patients who are hospitalized and require immediate treatment for liver-related conditions. They ensure the availability of various formulations and dosages, catering to the diverse needs of patients in clinical settings. The close relationship between hospital pharmacies and healthcare providers allows for quick access to medications, which is crucial in emergency situations. Moreover, hospital pharmacies often engage in clinical research and trials, contributing to the development of new treatment protocols and enhancing their role in managing liver diseases effectively. As the number of hospital admissions for liver conditions continues to rise, hospital pharmacies are expected to maintain a significant share in the UDCA drugs market.

Retail Pharmacies :

Retail pharmacies serve as a vital distribution channel for UDCA drugs, providing easy access for patients requiring outpatient care. They are often the first point of contact for patients seeking medications for liver-related ailments, making them essential for increasing patient awareness and adherence to prescribed treatments. Retail pharmacies typically stock a range of UDCA formulations, allowing patients to choose their preferred form of medication. Additionally, the increasing trend of self-medication and consulting pharmacists for drug-related queries is boosting the role of retail pharmacies in the UDCA market. With the ongoing expansion of retail pharmacy networks, this channel is expected to continue growing and facilitate wider distribution of UDCA drugs.

Online Pharmacies :

Online pharmacies are rapidly gaining traction as a distribution channel for UDCA drugs, driven by the convenience they offer to patients. The ease of ordering medications from home, coupled with the ability to compare prices and access a broader range of products, makes online pharmacies a popular choice among consumers. They also provide crucial information about medications, including dosage instructions and potential side effects, fostering informed decision-making among patients. As telehealth services expand, online pharmacies are likely to become more integrated into healthcare delivery, enhancing their role in medication distribution. Additionally, the COVID-19 pandemic has accelerated the shift toward online purchasing, making it a significant segment of the UDCA drugs market.

Drug Stores :

Drug stores are a traditional distribution channel for many pharmaceuticals, including UDCA drugs. They typically stock a variety of over-the-counter and prescription medications, making them accessible to a broad demographic of patients. Drug stores often collaborate with healthcare providers to ensure that patients receive the right medications for their conditions, which is particularly important for management of chronic diseases like liver disorders. The convenience of purchasing medications in a local drug store continues to attract patients, especially those who prefer in-person consultations with pharmacists. As the demand for UDCA drugs grows, drug stores are likely to maintain their relevance as a key distribution channel within the market.

Others :

Other distribution channels include specialty pharmacies, which cater to specific patient needs and typically stock high-cost or rare medications, and health and wellness stores, which may carry UDCA formulations focused on liver health. These alternative channels are becoming increasingly important as patients seek out targeted treatments for specific health concerns. Specialty pharmacies often provide additional services, such as medication management and patient counseling, which can enhance patient adherence and outcomes. As the awareness of liver health continues to grow, these 'Others' channels are likely to play a more prominent role in the distribution of UDCA drugs, supporting overall market expansion.

By Ingredient Type

Generic :

The generic segment of the UDCA drugs market is witnessing significant growth, primarily due to the cost-effectiveness of generic medications. As patent protections for branded UDCA drugs expire, generic options become available, making treatments more affordable for a broader patient population. This shift towards generic options is particularly crucial in regions with stringent healthcare budgets, where cost considerations play a significant role in treatment decisions. Moreover, the increasing acceptance of generic drugs by healthcare providers and patients alike, coupled with the robust quality control regulations ensuring their efficacy, is driving growth in this segment. The generic market not only increases patient access to UDCA but also encourages healthy competition among pharmaceutical companies, resulting in better pricing and availability of treatments.

Branded :

The branded segment remains an essential part of the UDCA drugs market, offering formulations that may include proprietary formulations, enhanced bioavailability, or added therapeutic benefits not found in generic versions. Patients often perceive branded medications as having greater reliability due to established brand names and perceived quality assurance. Pharmaceutical companies invest heavily in marketing branded UDCA drugs, particularly in regions where brand loyalty is strong and patient trust in well-known products is paramount. Additionally, the development of new branded formulations with improved efficacy or targeted delivery systems is likely to drive growth in this segment. As healthcare systems evolve, the continued presence of branded UDCA drugs will play a vital role in providing high-quality treatment options for patients suffering from liver-related conditions.

By Region

North America currently dominates the UDCA drugs market, accounting for approximately 45% of the total market share. The region's advanced healthcare infrastructure, high rates of chronic liver diseases, and significant healthcare spending are primary drivers of this dominance. The increasing prevalence of obesity-related liver conditions and diseases such as primary biliary cholangitis is also contributing to the rising demand for UDCA drugs in North America. Moreover, the presence of key players in the pharmaceutical industry, robust research and development initiatives, and favorable reimbursement policies further bolster market growth. With a CAGR of 5.8%, North America is expected to maintain its lead in the UDCA market through 2028.

Europe holds the second-largest share of the UDCA drugs market, accounting for approximately 30% of the overall market. The region benefits from a well-established healthcare system and significant awareness regarding liver health and disease management. The growing aging population, alongside increasing incidences of liver diseases, is driving demand for effective UDCA treatments. Furthermore, countries like Germany, France, and the UK are witnessing advancements in clinical practices and patient care, enhancing the adoption of UDCA as a first-line treatment for conditions like gallstones and primary biliary cholangitis. The European market is projected to grow at a CAGR of 4.7%, reflecting strong prospects for the UDCA drugs segment.

Opportunities

The UDCA drugs market presents numerous opportunities for growth and expansion, particularly in the realms of research and development. As ongoing studies continue to reveal the potential benefits of UDCA in treating a wider array of liver conditions, pharmaceutical companies have the opportunity to innovate and diversify their product offerings. This may include developing new formulations with enhanced bioavailability, targeted delivery systems, or adjunct therapies that combine UDCA with other agents to optimize treatment outcomes. Additionally, the growing focus on personalized medicine in the healthcare sector presents a unique opportunity for UDCA manufacturers to tailor therapies to individual patient needs, further enhancing treatment efficacy and patient satisfaction.

Furthermore, the increasing digitalization of healthcare, particularly in the wake of the COVID-19 pandemic, provides a significant opportunity for UDCA drugs to reach a broader audience. The rise of telemedicine and online health consultations allows for better patient education and access to medications through online pharmacies. Pharmaceutical companies can capitalize on this trend by enhancing their digital marketing strategies and establishing partnerships with telehealth platforms to ensure that UDCA drugs are readily accessible to patients in need. As more patients turn to online resources for healthcare solutions, this shift could potentially lead to substantial growth in the UDCA drugs market.

Threats

Despite the opportunities present in the UDCA drugs market, several threats could hinder its growth trajectory. One of the most significant threats is the increasing competition from alternative therapies and emerging treatment options for liver diseases. As research advances, new medications may offer improved efficacy or reduced side effects compared to UDCA, potentially impacting market share and revenues for existing UDCA drugs. Additionally, the rising prevalence of counterfeit drugs poses a threat to patient safety and brand integrity, which can undermine consumer confidence in UDCA products. Stringent regulatory requirements and the need for extensive clinical evidence to support new drug formulations can further complicate the development process, leading to increased costs and extended timelines for market entry.

Another critical concern for the UDCA drugs market is the potential for changes in healthcare policies and reimbursement structures. Fluctuations in government healthcare funding or shifts in insurance coverage could adversely affect patient access to UDCA treatments. In particular, budget constraints in public healthcare systems may lead to the prioritization of cost-effective alternatives, which may not include UDCA. The overall economic landscape, including the potential impact of global economic downturns, could further exacerbate these challenges, leading to reduced healthcare spending and lower demand for non-essential medications, including UDCA drugs.

Competitor Outlook

• Hepatica
• Sun Pharmaceutical Industries Ltd.
• Mylan N.V.
• Qilu Pharmaceutical Co., Ltd.
• Teva Pharmaceutical Industries Ltd.
• Hikma Pharmaceuticals PLC
• GSK (GlaxoSmithKline) PLC
• AbbVie Inc.
• Merck & Co., Inc.
• Dr. Reddy's Laboratories
• Amgen Inc.
• Actavis, Inc.
• Fresenius Kabi AG
• Intas Pharmaceuticals Ltd.
• Stada Arzneimittel AG

The competitive landscape of the UDCA drugs market is characterized by the presence of several key players, each vying for market share and striving to enhance their product offerings. The market is primarily dominated by large pharmaceutical companies with extensive research and development capabilities. These companies invest heavily in clinical trials and innovative formulations to position their products effectively in the market. The competition is further intensified by the entry of generic manufacturers, which aim to provide cost-effective alternatives to branded UDCA drugs. This has led established players to focus on brand loyalty and differentiation strategies to retain their customer base.

Sun Pharmaceutical Industries Ltd. is one of the leading companies in the UDCA market, known for its extensive portfolio of liver-related medications. The company has invested heavily in research and development, focusing on enhancing the efficacy and safety profiles of its UDCA formulations. Similarly, Mylan N.V. has established itself as a major player, offering a range of generic UDCA drugs that provide accessible treatment options for patients. Their strategic collaborations and partnerships with healthcare providers have significantly contributed to their market presence.

Furthermore, companies like Teva Pharmaceutical Industries Ltd. and AbbVie Inc. are continuously expanding their product lines through strategic acquisitions and partnerships. They focus on innovative marketing strategies and clinical research initiatives to maintain competitive advantages. The competitive landscape is expected to evolve further as new entrants join the market and existing players enhance their research capabilities to meet the growing demand for effective liver disease treatments. As the market dynamics shift, collaboration and innovation will remain essential for sustaining success in the UDCA drugs market.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 Hepatica
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 Amgen Inc.
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 Mylan N.V.
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 AbbVie Inc.
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Actavis, Inc.
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Fresenius Kabi AG
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Merck & Co., Inc.
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Stada Arzneimittel AG
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Dr. Reddy's Laboratories
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 GSK (GlaxoSmithKline) PLC
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Hikma Pharmaceuticals PLC
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Intas Pharmaceuticals Ltd.
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Qilu Pharmaceutical Co., Ltd.
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Sun Pharmaceutical Industries Ltd.
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Teva Pharmaceutical Industries Ltd.
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Drugs of UDCA Market, By Application
    • 6.1.1 Gallstones
    • 6.1.2 Primary Biliary Cholangitis
    • 6.1.3 Liver Diseases
    • 6.1.4 Cystic Fibrosis
    • 6.1.5 Others
  • 6.2 Drugs of UDCA Market, By Product Type
    • 6.2.1 Tablets
    • 6.2.2 Capsules
    • 6.2.3 Injectable
    • 6.2.4 Suspension
    • 6.2.5 Gel
  • 6.3 Drugs of UDCA Market, By Ingredient Type
    • 6.3.1 Generic
    • 6.3.2 Branded
  • 6.4 Drugs of UDCA Market, By Distribution Channel
    • 6.4.1 Hospital Pharmacies
    • 6.4.2 Retail Pharmacies
    • 6.4.3 Online Pharmacies
    • 6.4.4 Drug Stores
    • 6.4.5 Others

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Drugs of UDCA Market by Region
  • 10.4 Latin America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 Brazil
      • 10.4.1.2 Argentina
      • 10.4.1.3 Mexico
  • 10.5 North America - Market Analysis
    • 10.5.1 By Country
      • 10.5.1.1 USA
      • 10.5.1.2 Canada
  • 10.6 Middle East & Africa - Market Analysis
    • 10.6.1 By Country
      • 10.6.1.1 Middle East
      • 10.6.1.2 Africa

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Drugs of UDCA market is categorized based on

By Product Type

• Tablets
• Capsules
• Injectable
• Suspension
• Gel

By Application

• Gallstones
• Primary Biliary Cholangitis
• Liver Diseases
• Cystic Fibrosis
• Others

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Drug Stores
• Others

By Ingredient Type

• Generic
• Branded

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Hepatica
• Sun Pharmaceutical Industries Ltd.
• Mylan N.V.
• Qilu Pharmaceutical Co., Ltd.
• Teva Pharmaceutical Industries Ltd.
• Hikma Pharmaceuticals PLC
• GSK (GlaxoSmithKline) PLC
• AbbVie Inc.
• Merck & Co., Inc.
• Dr. Reddy's Laboratories
• Amgen Inc.
• Actavis, Inc.
• Fresenius Kabi AG
• Intas Pharmaceuticals Ltd.
• Stada Arzneimittel AG